Price
$286.20+7.68%Social Signal Score
Analyst Ratings
44 analysts52-week range
- Last close
- $286.20
- Off 52w high
- -3.0%
- 200-day average
- $242.45
- vs 200-day
- +18.0%
Revenue
$17.40B+156.09%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert A. Michael
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 57,000
- Beta
- 0.28
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 2.63
Financials
Revenue
$17.40B+156.1%Net Income
$4.22B+203.2%EBITDA
$7.49B+183.6%Free Cash Flow
$7.30B+411.9%EPS (diluted)
$2.38+180.0%Shares Outstanding (diluted)
1.77B+9.2%Operating Expenses
$6.87BCash & Debt
$10.77BReturn of Capital
$3.08BRevenue by Segment (annual)
$58.17BDividend per Share
$1.82Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $61.16B | $4.23B | $2.37 |
| 2024 | $56.33B | $4.28B | $2.40 |
| 2023 | $54.32B | $4.86B | $2.73 |
| 2022 | $58.05B | $11.84B | $6.65 |
| 2021 | $56.20B | $11.54B | $6.48 |
| 2020 | $45.80B | $4.62B | $2.73 |
| 2019 | $33.27B | $7.88B | $5.30 |
| 2018 | $32.75B | $5.69B | $3.69 |
| 2017 | $28.22B | $5.31B | $3.31 |
| 2016 | $25.64B | $5.95B | $3.65 |
| 2015 | $22.86B | $5.14B | $3.15 |
| 2014 | $19.96B | $1.77B | $1.11 |
| 2013 | $18.79B | $4.13B | $2.58 |
| 2012 | $18.38B | $5.28B | $3.35 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ABBV's reported EPS growth of -2.6% a year over 13 years.
- EPS in 5 years
- $2.09
- Implied price
- $37.59
- Return from $286.20
- -33.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $18.69 — -93.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -12.6% | -44.9% | -42.4% | -40.2% | -38.3% | -36.7% |
| -7.6% | -41.7% | -39.1% | -36.8% | -34.8% | -33.0% |
| -2.6% | -38.6% | -35.8% | -33.4% | -31.3% | -29.4% |
| 2.4% | -35.4% | -32.5% | -29.9% | -27.8% | -25.8% |
| 7.4% | -32.3% | -29.2% | -26.5% | -24.2% | -22.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
69+34.30%Social Signal Score
Mentions (100)
- News (RSS)fool·1d ago·Neutral
AbbVie (ABBV) Stock Just Got a 5.2% Dividend Increase. Here's How Many Shares You Need to Generate $1,000 a Year. This pharmaceutical giant has hiked its payout for 53 years in a row, so it's likely to keep doing so.
View source ↗ - News247wallst.com·1d ago·Negative
$500,000 in AbbVie and Gilead Could Pay More Than $11,000 a Year in Dividends One drugmaker's earnings look broken on paper, while the other carries negative equity and a mountain of new debt. Both still hand retirees raises every year, so why would anyone trust them with half a million dollars?
View source ↗ - Newsfool.com·1d ago·Positive
AbbVie (ABBV) Stock Just Got a 5.2% Dividend Increase. Here's How Many Shares You Need to Generate $1,000 a Year. AbbVie's dividend yield of 2.4% is solid, but more importantly, it's been growing at an impressive clip. The stock isn't cheap, but it warrants consideration for a long-term portfolio.
View source ↗ - Newsdefenseworld.net·1d ago·Neutral
Top Pharmaceutical Stocks To Add to Your Watchlist – November 19th Eli Lilly and Company, Insmed, Johnson and Johnson, Merck and Co., Inc., AbbVie, Pfizer, and SELLAS Life Sciences Group are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, or sell prescription and other medicines. For investors, they offer exposure to
View source ↗ - Newsfool.com·2d ago·Positive
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027? AbbVie generates significant cash flow from its newer immunology stars, Skyrizi and Rinvoq. Eli Lilly is seeing explosive revenue growth driven by its dominant presence in the metabolic health market.
View source ↗ - Newsprnewswire.com·2d ago·Neutral
AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference NORTH CHICAGO, Ill., Nov. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026.
View source ↗ - News (RSS)zerohedge·3d ago·Neutral
… memory costs bite; Microsoft and Intel signed a long-term Azure infrastructure pact; UniCredit struck a deal with the German government on its Commerzbank takeover; AbbVie is targeting solid tumors in a deal worth up to $2.54 billion; Starboard sees more upside in Flowserve and Riot Platforms; Apollo scrapped a planned $2 billion loan to Manchester City's owner, according to the FT; UGI will spin off its global LPG business; and Moody's lowered its outlook on Nvidia's credit to stable from posi…
View source ↗ - News247wallst.com·4d ago·Neutral
Invest $100,000 in These 4 Dividend Stocks and Collect Passive Income for Life Four blue-chip dividend payers, including one that sends checks monthly, offer a way to keep the shares and still get paid.
View source ↗ - Newszacks.com·5d ago·Neutral
How Did AbbVie's Neuroscience Franchise Perform in Q3? ABBV's neuroscience franchise delivers 19.5% operational sales growth in Q3, prompting the company to raise its 2026 segment sales outlook to $13 billion.
View source ↗ - Newszacks.com·5d ago·Neutral
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - News (Marketaux)dividend-growth-stocks.com·9d ago·Neutral
Abbvie Inc. (ABBV) Dividend Stock Analysis Abbvie Inc. (ABBV) Dividend Stock Analysis
View source ↗ - News (Marketaux)gurufocus.com·13d ago·Positive
AbbVie (ABBV) Reports Positive Clinical Trial Results on GLP-1 Weight-Loss Medications Impacting Cosmetic Satisfaction On November 08, 2026, AbbVie <e[+257 characters]
View source ↗ - News (RSS)seekingalpha·13d ago·Negative
AbbVie reports improved facial satisfaction among weight-loss drug users
View source ↗ - Newszacks.com·17d ago·Neutral
2 Defensive Healthcare Stocks Hitting New 52-Week Highs: ABBV & LLY As tech stocks retreat, AbbVie (ABBV) and Eli Lilly (LLY) are hitting fresh 52-week highs, offering investors defensive healthcare exposure with compelling growth potential.
View source ↗ - News247wallst.com·17d ago·Neutral
5 High-Yield Dividend Stocks Paying Up to 6% With Payouts Built to Last A fat yield means nothing if the check bounces. Five payers across telecom, tobacco, pharma, real estate and pipelines show how to test coverage, and one of them carries a debt pile that could threaten its raise streak.
View source ↗ - Newszacks.com·18d ago·Positive
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - News (Marketaux)manilatimes.net·18d ago·Positive
Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026 Reason for the revision Nxera Pharma UK[+274 characters]
View source ↗ - News247wallst.com·18d ago·Neutral
Exxon Mobil Just Raised Its Dividend for the 44th Year. Here Are 3 More Wall Street Favorites Four dividend stocks just delivered strong earnings, but free cash flow and balance sheet strength separate the ones built to keep raising payouts from the ones that just look good on paper.
View source ↗ - Newsreuters.com·19d ago·Neutral
AbbVie expands Oxford R&D facility as part of £120 million-plus investment AbbVie expands Oxford R&D facility as part of £120 million-plus investment
View source ↗ - News247wallst.com·19d ago·Neutral
AbbVie Hit a New High After Earnings. There's More Upside Left. AbbVie just logged a 33% gain for the year and raised its guidance again, but the real question is whether Skyrizi and a newly closed pipeline deal can push shares even further past a valuation that already looks stretched.
View source ↗ - Newsprnewswire.com·19d ago·Negative
… insights from the Allergan Aesthetics "What Consumers Really Want" report IRVINE, Calif., Nov. 3, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present nine abstracts at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting, Nov. 5-8 in San Diego, underscoring the company's continued investment in generating scientific evidence to inform care across multiple aesthetic categories.
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test AbbVie TodayABBVAbbVie$288.82 -6.07 (-2.06%) As of 01:16 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$190.75▼$298.74Dividend Yield2.40%P/E Ratio49.69Price Target$285.89Add to WatchlistBelieve it or not, Humira still drives headlines for AbbVie NYSE: ABBV, despite contributing little to the company's growth.
View source ↗ - Newsfool.com·20d ago·Neutral
The Best Dividend Stocks to Buy With $5,000 in November AbbVie survived its loss of Humira, and its profits are soaring. J&J's streamlining efforts are paying off.
View source ↗ - Newszacks.com·20d ago·Neutral
ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress AbbVie raises its 2026 revenue and earnings outlook as Skyrizi, Rinvoq and neuroscience growth fuel momentum, while oncology milestones shape prospects.
View source ↗ - News247wallst.com·20d ago·Neutral
4 Elite Dividend Stocks That Pay You Passive Income Every Quarter When you're drawing income from a portfolio, the check size matters less than whether it keeps coming every year. A blue-chip payout is funded by free cash flow left over after the business reinvests in itself.
View source ↗ - Newsbenzinga.com·20d ago·Positive
These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results AbbVie Inc. (NYSE:ABBV) on Friday reported better-than-expected third-quarter 2026 results and raised its full-year outlook.
View source ↗ - Newsfool.com·20d ago·Negative
Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo AbbVie's ABBV-466 nearly doubled Skyrizi's Crohn's remission rate in a Phase 2 study. Analysts see it as a potentially more effective follow-up to Skyrizi.
View source ↗ - Newsseekingalpha.com·22d ago·Neutral
Emerson Among 14 Dividend Growth Companies To Announce Annual Dividend Increases In First Half Of November Emerson is set to extend its dividend growth streak to 70 years, with a predicted 6.3–8.1% increase driven by a business transformation. EMR's shift to higher-margin Intelligent Devices and Software & Control segments supports a rebound in adjusted EPS, forecasted to grow 19% this year. Dividend growth across the broader group of long-term payers remains mostly mid-single digits, but severa
View source ↗ - Newsfool.com·22d ago·Neutral
AbbVie: 3 Key Takeaways for Long-Term Investors AbbVie raised full-year net revenue guidance to $67.8 billion. Skyrizi and Rinvoq delivered $6 billion in combined growth this year.
View source ↗ - Newsfool.com·22d ago·Neutral
Is AbbVie a Buy After Its Latest Earnings Report? Adjusted EPS nearly doubled, but most of that comes from last year's big research-deal charge, and underlying growth was closer to 17%. Skyrizi and Rinvoq now account for nearly half of AbbVie's revenue, which drives growth and concentrates risk.
View source ↗ - Newsseekingalpha.com·23d ago·Neutral
Dividend Champion, Contender, And Challenger Highlights: Week November 1 A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.
View source ↗ - News (RSS)fool·23d ago·Positive
AbbVie (ABBV) Q3 2026 Earnings Call Transcript Skyrizi and Rinvoq drive double-digit growth as management raises full-year guidance.
View source ↗ - News (RSS)seekingalpha·23d ago·Neutral
AbbVie: Why I See More Upside After Q3
View source ↗ - Newsseekingalpha.com·23d ago·Positive
AbbVie Inc. (ABBV) Q3 2026 Earnings Call Transcript AbbVie Inc. (ABBV) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·23d ago·Neutral
What AbbVie (ABBV) Said on Its Q3 Earnings Call AbbVie NYSE: ABBV reported third-quarter 2026 results above its guidance midpoint and raised its full-year revenue and adjusted earnings outlook, citing continued growth from its immunology and neuroscience portfolios.
View source ↗ - Newsseekingalpha.com·23d ago·Positive
AbbVie: Why I See More Upside After Q3 AbbVie Inc. reported strong third-quarter results. ABBV's revenue increased 10.3% YoY, while non-GAAP EPS rose 105.4%. Skyrizi, AbbVie's IL-23 antagonist, generated $5.78 billion in sales, representing 22.7% year-over-year growth.
View source ↗ - Newszacks.com·23d ago·Positive
ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS View AbbVie beats Q3 earnings and revenue estimates as strong immunology and neuroscience sales drive growth, prompting a higher 2026 EPS outlook.
View source ↗ - News (RSS)zerohedge·23d ago·Neutral
…9:45am, est. 56, prior 58.8). Fed speaker slate includes Barkin on Sirius XM (9:30am), Daly (12pm) and Musalem (12:30pm). On the earnings front, ExxonMobil, Chevron, AbbVie, Colgate-Palmolive, Regeneron, General Dynamics, LyondellBasell, Dominion Energy and Cboe report before the open.Market SnapshotTop Overnight NewsDisappointing reports from technology heavyweights including Amazon.com have fueled fears over massive AI spending, with Nasdaq 100 constituents already wiping out more than $1.2 tr…
View source ↗ - Newszacks.com·23d ago·Neutral
Here's What Key Metrics Tell Us About AbbVie (ABBV) Q3 Earnings While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - News247wallst.com·23d ago·Neutral
CDs Offer Fixed Interest. AbbVie Offers a Growing Dividend. AbbVie just handed shareholders their latest raise while your CD rate sits frozen, but the comparison between a guaranteed payment and a growing dividend gets complicated fast once taxes, price swings, and reinvestment risk enter the picture.
View source ↗ - Newszacks.com·23d ago·Positive
AbbVie (ABBV) Tops Q3 Earnings and Revenue Estimates AbbVie (ABBV) came out with quarterly earnings of $3.82 per share, beating the Zacks Consensus Estimate of $3.74 per share. This compares to earnings of $1.86 per share a year ago.
View source ↗ - Newswsj.com·23d ago·Neutral
AbbVie Revenue Rises on Strength in Immunology, Neuroscience The pharmaceutical company boosted its profit outlook for the year, and raised its quarterly dividend as both third-quarter results and full-year guidance came in above expectations.
View source ↗ - Newsprnewswire.com·23d ago·Negative
…26 Announces 2027 Dividend Increase of 5.2 Percent, Beginning with Dividend Payable in February 2027 NORTH CHICAGO, Ill., Oct. 30, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2026.
View source ↗ - News247wallst.com·24d ago·Negative
AbbVie Stock: What 10 Years of Growth and Dividends Did for $1,000 AbbVie built its empire on a single blockbuster drug, then watched biosimilars gut it almost overnight.
View source ↗ - Newsseekingalpha.com·24d ago·Negative
Best Dividend Aristocrats For November 2026 Dividend Aristocrats underperformed SPY in September but rebounded sharply in October, narrowing the YTD gap. NOBL and the average Aristocrat have YTD returns of 13.13% and 13.35%, trailing SPY's 14.15%. Dividend growth among Aristocrats accelerated, with the 2026 average increase now at 4.55%, bolstered by recent double-digit hikes.
View source ↗ - News247wallst.com·25d ago·Positive
Retire on Dividends: 5 High-Yield Stocks Boomers Are Buying and Holding Forever Treasury yields near 5% make dividend stocks work harder to justify their risk, yet five companies spanning tobacco, pipelines, telecom, pharma, and net-lease real estate have kept raising their payouts through every rate spike in recent memory.
View source ↗ - Newszacks.com·26d ago·Negative
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.
View source ↗ - Newszacks.com·26d ago·Neutral
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings AbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise near-term concerns.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
AbbVie: Analyzing Performance, Pipeline, And Pricing Ahead Of Q3 (Strong Buy) AbbVie Inc. is trading at all-time highs, with robust 2026 guidance and a market cap exceeding $500bn. I expect ABBV Q3 earnings to outperform, driven by immunology assets Skyrizi and Rinvoq, which together will generate over $30bn in 2026. Despite an aging portfolio and pipeline concerns, ABBV's near-term growth and profit margins remain industry-leading, justifying a raised valuation target.
View source ↗ - Newszacks.com·26d ago·Negative
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
View source ↗ - Newsprnewswire.com·26d ago·Neutral
Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA) Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 million in grants to fuel business growth and empower confidence. In 2026 alone, BOTOX® Cosmetic awarded 20 women entrepreneurs each with a $20,000 grant to help advance their business goals.
View source ↗ - Newsprnewswire.com·26d ago·Negative
…iple myeloma portfolio that addresses disease complexity and supports patients' evolving care goals NORTH CHICAGO, Ill., Oct. 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for etentamig, a second-generation BCMA x CD3 bispecific antibody T-cell engager administered intravenously for the treatment of adults with relapsed or refractory multiple myeloma.1 BCMA-directed bispecific a…
View source ↗ - News (RSS)zerohedge·27d ago·Neutral
…x (Wednesday) and Samsung Electronics (Thursday) earning will have global ramifications from the tech sector, while healthcare earnings includes Novartis, Eli Lilly, AbbVie, AstraZeneca and Sanofi; energy includes Shell, TotalEnergies, ExxonMobil, Chevron and BP; and autos include Porsche, Ford, Mercedes-Benz and Volkswagen. In Asia, the KOSPI (-0.90%) is leading declines as weakness in technology shares weighs on sentiment. Elsewhere, the Nikkei (-0.34%), CSI 300 (-0.47%), and Shanghai Composit…
View source ↗ - News247wallst.com·27d ago·Negative
AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30 AbbVie (NYSE:ABBV | ABBV Price Prediction) reports third-quarter results before the open on October 30. Shares are up 28.55% year to date, and options pricing implies a roughly 5% move on the release.
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Best Dividend Kings: October 2026 Dividend Kings have outperformed SPY YTD, rising 13.5% versus SPY's 12.32%, with a strong October rebound. Twenty-six Dividend Kings appear both potentially undervalued and offer long-term annualized expected returns of at least 10%. Dividend growth for the Kings in 2026 averages 4.65%, with recent increases from GRC, NWN, and RPM.
View source ↗ - Newsetftrends.com·28d ago·Negative
A Worthwhile Exit Strategy This week could mark something that hasn't happened to me in years—I may end up selling my shares of AbbVie (ABBV) at a price below the market value. It's all going to depend on if the share price ends the week above $280.
View source ↗ - Newsprnewswire.com·30d ago·Negative
…care providers to use clinical judgment when determining whether tuberculosis (TB) testing is needed NORTH CHICAGO, Ill., Oct. 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease (CD)iv.
View source ↗ - News247wallst.com·30d ago·Negative
AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's? When a drugmaker's top product loses patent protection, the dividend usually takes the hit.
View source ↗ - News247wallst.com·30d ago·Neutral
Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different Treasury yields have turned dividend investing into a minefield, but five mega-caps have quietly raised their payouts through every rate spike, recession, and patent cliff of the past four decades.
View source ↗ - Newsseekingalpha.com·30d ago·Positive
The Dividend Aristocrats Ranked By Quality Scores (October 2026) I rank all 69 S&P 500 Dividend Aristocrats by my 9F Quality Scores, segmenting them into undervalued, fairly valued, and overvalued groups. My consensus fair value estimates, blending up to 40 data points per stock, highlight 12 undervalued and 18 fairly valued Aristocrats, with 39 currently overvalued. Investment candidates vary by style: ADP, BRO, and NDSN for growth; NEE for total return; PEP and O for income; CAT and GWW for pa
View source ↗ - Newszacks.com·30d ago·Neutral
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - News (RSS)fool·31d ago·Neutral
Great News for AbbVie Stock Investors The company is gearing up for future major patent cliffs.
View source ↗ - Newsfool.com·31d ago·Neutral
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer Both companies pay relatively high-yield dividends. One marries this with growing fundamentals, while the other is basically in reset mode.
View source ↗ - Newsfool.com·31d ago·Positive
Great News for AbbVie Stock Investors AbbVie posted strong Phase 2a results for a potential successor to Skyrizi in Crohn's disease. The company also has a promising eczema candidate that could cement its position in immunology.
View source ↗ - Newszacks.com·31d ago·Neutral
AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
View source ↗ - News (RSS)seekingalpha·31d ago·Positive
AbbVie: Skyrizi And Rinvoq Keep Delivering As Oncology Gains Momentum
View source ↗ - Newsreuters.com·31d ago·Negative
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
View source ↗ - Newsprnewswire.com·31d ago·Neutral
…1α and IL-1β as a potential treatment approach in adults and adolescents with moderate to severe HS1 NORTH CHICAGO, Ill., Oct. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin (IL) 1α/1β antagonist, in adults and adolescents with moderate to severe hidradenitis suppurativa (HS).
View source ↗ - News (Marketaux)gurufocus.com·32d ago·Neutral
Capital Group Core Equity (CGUS) Adds NVDA and MSFT on Oct. 19 Stock Shares changed Value Position ELI [+331 characters]
View source ↗ - Newsfool.com·32d ago·Positive
AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue? AbbVie currently looks stronger on revenue by consistently generating higher overall totals and demonstrating a faster growth trajectory across the measured periods. Both companies record quarter-over-quarter declines at the start of the year, but they maintain generally upward trajectories over the last eight quarters, with AbbVie showing wider increases.
View source ↗ - News247wallst.com·32d ago·Positive
Forget Social Security: 5 High-Yield Stocks Retirees Are Buying Instead Social Security raises are locked to a government formula, but a growing number of retirees are routing their income strategy around it entirely, and the stocks they are buying span five very different industries.
View source ↗ - News (RSS)forbes·32d ago·Neutral
McLaren Teams Up With AbbVie Before Formula 1 United States GP At COTA As Formula 1 races into Austin, Texas for the United States Grand Prix at Circuit of the Americas, McLaren and AbbVie of North Chicago, Illinois announce a partnership.
View source ↗ - News (RSS)fool·33d ago·Positive
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.
View source ↗ - Newsfool.com·33d ago·Negative
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? AbbVie generates massive free cash flow while successfully navigating the loss of exclusivity for its top-selling drug. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while expanding into gene editing and pain management.
View source ↗ - Newsseekingalpha.com·33d ago·Neutral
15 Undervalued Stocks: Yield Up To 7.8% And 15 Overvalued Not To Pursue Now Rose's Income Garden portfolio review highlights 15 most undervalued and 15 most overvalued dividend stocks using 52-week high/low analysis. Energy names like XOM, SHEL, and CVX have rotated into overvalued territory, while high-yield REITs such as VICI remain top undervalued picks. Dividend yield remains a key selection criterion, with several undervalued stocks offering yields above 5% and investment-grade credit ratin
View source ↗ - Newszacks.com·34d ago·Negative
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results ABBV's neuroscience franchise targets nearly 16% revenue growth in Q3, with established drugs and newer Parkinson's therapies driving expansion.
View source ↗ - Newsprnewswire.com·34d ago·Negative
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary endpoint. The treatment difference between ABBV-466 and the monotherapy groups further increased at Week 24 1 Gene exp…
View source ↗ - News (Marketaux)gurufocus.com·34d ago·Positive
AbbVie (ABBV) to Showcase Expanded Solid Tumor Research at ESMO Congress On October 18, 2026, AbbVie <em[+254 characters]
View source ↗ - Newsprnewswire.com·35d ago·Positive
… from multiple assets across various stages of development Presentations across investigational and approved medicines to feature Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Emrelis™ (telisotuzumab vedotin-tllv) and Elahere ® (mirvetuximab soravtansine-gynx) NORTH CHICAGO, Ill., Oct. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society f…
View source ↗ - News (Marketaux)gurufocus.com·35d ago·Positive
AbbVie (ABBV) Showcases Long-Term IBD Data at UEG Week 2026 On October 18, 2026, AbbVie <em[+224 characters]
View source ↗ - Newsfool.com·35d ago·Positive
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. It was Griffin's biggest add for Citadel last quarter.
View source ↗ - News (RSS)fool·36d ago·Positive
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle Rising rates can expose dividend traps, but this Dividend King is built to keep paying.
View source ↗ - News247wallst.com·36d ago·Positive
AbbVie's Dividend Keeps Climbing. Is It Still a Buy for Income Investors? AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing.
View source ↗ - Newsfool.com·36d ago·Negative
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle AbbVie is the exact opposite of a high-yield trap. Its top two drugs together generate more than enough revenue to cover the dividend.
View source ↗ - Newsgurufocus.com·36d ago·Positive
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
View source ↗ - News (RSS)fool·37d ago·Neutral
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends You'd need to invest over $200,000 in the pharma leader at its current price.
View source ↗ - Newsfool.com·37d ago·Positive
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends AbbVie is a resilient Dividend King with a wide moat. It still looks cheap relative to its long-term growth potential.
View source ↗ - News (Marketaux)gurufocus.com·37d ago·Neutral
AbbVie (ABBV) Expands Board to 13 Directors with Appointment of Dr. John M. Carethers AbbVie Inc. ABBV annou[+286 characters]
View source ↗ - News (RSS)marketwatch·38d ago·Negative
Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.
View source ↗ - News (RSS)fool·38d ago·Negative
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.
View source ↗ - Newsfool.com·38d ago·Negative
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie's newer drugs are growing fast enough to more than replace Humira revenue. The hardest part of the transition appears to be behind it.
View source ↗ - Newszacks.com·39d ago·Neutral
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
View source ↗ - News247wallst.com·39d ago·Negative
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.
View source ↗ - News (RSS)fool·40d ago·Positive
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? One faces patent cliffs and revenue concentration; the other dominates a booming market but trades at a premium valuation.
View source ↗ - Newsgurufocus.com·40d ago·Neutral
A Look at AbbVie Inc (ABBV) After 2.4% Decline -- GF Value $222.10 vs Price $274.36 On October 13, 2026, AbbVie Inc (ABBV) shares fell 2.4% to a current price of $274.36. This decline occurs within a wider 52-week range of $190.75 to $283.43, r
View source ↗ - News (RSS)investing·40d ago·Neutral
AbbVie reports positive Crohn’s disease trial results for Skyrizi
View source ↗ - Newsfool.com·40d ago·Neutral
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? AbbVie is aggressively diversifying its pipeline to mitigate the revenue impact from its loss of patent exclusivity on Humira. Novo Nordisk maintains a dominant lead in the rapidly expanding metabolic health market through its blockbuster obesity treatments.
View source ↗ - News247wallst.com·40d ago·Negative
5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income Two of these five dividend stocks just took a beating in October, and that selloff quietly pushed their yields to levels that make the safer-looking names on the list look stingy by comparison.
View source ↗ - News (RSS)fool·40d ago·Positive
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.
View source ↗ - Newsfool.com·41d ago·Positive
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? AbbVie continues to diversify its portfolio through the successful expansion of newer therapies like Skyrizi and Rinvoq. Eli Lilly and has seen explosive growth driven by its dominant presence in the massive cardiometabolic treatment market.
View source ↗
Earnings
Wed, Feb 3(in 2 months)
Consensus estimate $3.88 per share
Typical surprise +2.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Oct 30$3.82 vs $3.73beat
- Fri, Jul 31$3.65 vs $3.61beat
- Wed, Apr 29$2.65 vs $2.59beat
- Wed, Feb 4$2.71 vs $2.65beat
- Fri, Oct 31$1.86 vs $1.77beat
- Thu, Jul 31$2.97 vs $2.88beat
Estimates and results for ABBV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ABBV officers and directors.
- Bought
- —
- Sold
- $30.8m
0 trades
7 trades
- Stewart Jeffrey Ryansold
- Donoghoe Nicholassold
- Purdue David Ryansold
- Siatis Perry Csold
- Siatis Perry Csold
- Siatis Perry Csold
- Siatis Perry Csold
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (33d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (35d later)Sell$15,001 - $50,000
- Pete Sessionshouse · TX17 · disclosed Sep 21, 2026 (7d later)Sell$15,001 - $50,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Jun 11, 2026 (41d later)Buy$15,001 - $50,000
- Josh Gottheimerhouse · NJ05 · disclosed Jun 4, 2026 (30d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$15,001 - $50,000
- Julie Johnsonhouse · TX32 · disclosed Jan 16, 2026 (29d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (447d later)Buy$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (36d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (354d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (260d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Dec 12, 2025 (29d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- John Boozmansenate · AR · disclosed Sep 12, 2025 (21d later)Sell$1,001 - $15,000
- John Boozmansenate · AR · disclosed Sep 12, 2025 (32d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Sep 12, 2025 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (39d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
